Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival

Author: Benzinga Newsdesk | July 02, 2024 07:37am

Posted In: JNJ

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/16/2024 Vestis Corporation (VSTS)

07/22/2024 Biogen Inc. (BIIB)